2004
The hepatotoxicity of non‐steroidal anti‐inflammatory drugs
Rubenstein JH, Laine L. The hepatotoxicity of non‐steroidal anti‐inflammatory drugs. Alimentary Pharmacology & Therapeutics 2004, 20: 373-380. PMID: 15298630, DOI: 10.1111/j.1365-2036.2004.02092.x.Peer-Reviewed Original ResearchConceptsNon-steroidal anti-inflammatory drug usersNon-steroidal anti-inflammatory drugsAnti-inflammatory drugsLiver injuryDrug usersParticular non-steroidal anti-inflammatory drugsComparative riskPopulation-based epidemiological studyRare complicationExcess riskRelevant hepatotoxicityInclusion criteriaMethodological qualityEpidemiological studiesPrecise riskPatient countsCumulative exposureInjuryHospitalizationDrugsRiskHepatotoxicityIncidenceCurrent useDeathThe epidemiology of ischaemic colitis
Higgins PD, Davis KJ, Laine L. The epidemiology of ischaemic colitis. Alimentary Pharmacology & Therapeutics 2004, 19: 729-738. PMID: 15043513, DOI: 10.1111/j.1365-2036.2004.01903.x.Peer-Reviewed Original ResearchConceptsIschemic colitisRisk factorsPopulation-based sampleGeneral populationPopulation incidenceChronic obstructive pulmonary diseaseCo-morbid conditionsIrritable bowel syndromeObstructive pulmonary diseasePopulation-based studyGeneral population incidenceBowel syndromePulmonary diseaseCase seriesBaseline incidenceCase reportAdvanced ageVascular surgeryColitisEligible articlesIncidencePopulation samplePrevalenceRiskBibliographic databases
2003
Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo
Hawkey C, Laine L, Simon T, Quan H, Shingo S, Evans J. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo. European Journal Of Gastroenterology & Hepatology 2003, 15: 835. DOI: 10.1097/00042737-200307000-00021.Peer-Reviewed Original Research
2000
Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double‐blind, placebo‐controlled trial
Hawkey C, Laine L, Simon T, Beaulieu A, Maldonado‐Cocco J, Acevedo E, Shahane A, Quan H, Bolognese J, Mortensen E. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double‐blind, placebo‐controlled trial. Arthritis & Rheumatism 2000, 43: 370-377. PMID: 10693877, DOI: 10.1002/1529-0131(200002)43:2<370::aid-anr17>3.0.co;2-d.Peer-Reviewed Original ResearchConceptsGastroduodenal ulcersPrespecified criteriaEffect of rofecoxibPlacebo-controlled trialSecondary end pointsDouble-blind studyGastroduodenal ulcerationGastroduodenal mucosaUlcer incidenceCyclooxygenase-2Side effectsUlcersEnd pointEffective doseRofecoxibWeeksPlaceboPatientsOsteoarthritisIncidenceDoseIbuprofenUlcerationMucosaEndoscopy